Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer

Robin M. J. M. van Geel, Emilie M. J. van Brummelen, Ferry A. L. M. Eskens, Sanne C. F. A. Huijberts, Filip Y. F. L. de Vos, Martijn P. J. K. Lolkema, Lot A. Devriese, Frans L. Opdam, Serena Marchetti, Neeltje Steeghs, Kim Monkhorst, Bas Thijssen, Hilde Rosing, Alwin D. R. Huitema, Jos H. Beijnen, Rene Bernards, Jan H. M. Schellens

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1166-1174
Number of pages9
JournalBritish Journal of Cancer
Issue number8
Publication statusPublished - Apr 2020


  • RAS
  • ARRY-142886
  • AZD6244

Cite this